Spruce Biosciences, Inc. appointed Adrian Quartel, M.D., FFPM, as its new Chief Medical Officer, replacing Dr. Kirk Ways, who will remain on the Board of Directors. Dr. Quartel has extensive experience in rare disease therapies and rare disease portfolio management. Spruce Biosciences, Inc. is a biotechnology company focused on developing treatments for rare diseases.
